Organogenesis Holdings (STU:2PQ) EPS (Basic): €-0.16 (TTM As of Mar. 2026)


STU:2PQ Organogenesis Holdings Inc STU:2PQ
67 GF Score
Price €2.12
GF Value €2.76
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings EPS (Basic)?

Organogenesis Holdings STU:2PQ -0.93% 67 EPS (Basic) is €-0.16 as of Mar. 2026. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.76 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Organogenesis Holdings's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.38. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.16.

Organogenesis Holdings's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.38. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.17.

Organogenesis Holdings's EPS without NRI for the three months ended in Mar. 2026 was €-0.38. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.15.

During the past 12 months, Organogenesis Holdings's average EPS without NRIGrowth Rate was -4200.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 22.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Organogenesis Holdings's highest 3-Year average EPS without NRI Growth Rate was 22.00% per year. The lowest was -43.70% per year. And the median was -24.80% per year.

Organogenesis Holdings  (STU:2PQ) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Organogenesis Holdings EPS (Basic) Related Terms

Organogenesis Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings EPS (Basic) Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.11 0.04 -0.01 0.14

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.09 0.09 0.21 -0.38
STU:2PQ
67GF Score
Organogenesis Holdings Inc STU:2PQ
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Organogenesis Holdings's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(31.625-9.249)/126.738
=0.18

Organogenesis Holdings's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-45.98-2.46)/127.797
=-0.38

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.16 mean?
Organogenesis Holdings (STU:2PQ) has a EPS (Basic) of €-0.16 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' EPS (Basic) too high?
Organogenesis Holdings' current EPS (Basic) is €-0.16. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' EPS (Basic) compare to SIGA and ELTP?
Organogenesis Holdings' EPS (Basic) of €-0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current EPS (Basic) is €-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.76, compared to a current price of €2.12 — trading 23.2% below its estimated fair value. The current EPS (Basic) is €-0.16. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current EPS (Basic) is €-0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.12 is trading 23.2% below its estimated GF Value™ of €2.76. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for STU:2PQ:

  • EPS (Basic): €-0.16
  • GF Value™: €2.76 vs. price of €2.12 (23.2% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges ORGO:USA2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for STU:2PQ

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.12
Price
€2.76
GF Value